Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros








Base de dados
Intervalo de ano de publicação
1.
Pediatr Blood Cancer ; 71(5): e30927, 2024 May.
Artigo em Inglês | MEDLINE | ID: mdl-38421306

RESUMO

BACKGROUND: Unusual olfactory perception, often referred to as "phantosmia" or "cacosmia" has been reported during brain radiotherapy (RT), but is infrequent and does not typically interfere with the ability to deliver treatment. We seek to determine the rate of phantosmia for patients treated with proton craniospinal irradiation (CSI) and identify any potential clinical or treatment-related associations. METHODS: We performed a retrospective review of 127 pediatric patients treated with CSI, followed by a boost to the brain for primary brain tumors in a single institution between 2016 and 2021. Proton CSI was delivered with passive scattering (PS) proton technique (n = 53) or pencil beam scanning technique (PBS) (n = 74). Within the PBS group, treatment delivery to the CSI utilized a single posterior (PA) field (n = 24) or two posterior oblique fields (n = 50). We collected data on phantom smell, nausea/vomiting, and the use of medical intervention. RESULTS: Our cohort included 80 males and 47 females. The median age of patients was 10 years (range: 3-21). Seventy-one patients (56%) received concurrent chemotherapy. During RT, 104 patients (82%) developed worsening nausea, while 63 patients (50%) reported episodes of emesis. Of those patients who were awake during CSI (n = 59), 17 (29%) reported phantosmia. In the non-sedated group, we found a higher rate of phantosmia in patients treated with PBS (n = 16, 42%) than PS (n = 1, 4.7%) (p = .002). Seventy-eight patients (61%) required medical intervention after developing nausea/vomiting or phantosmia during RT. Two patients required sedation due to the malodorous smell during CSI. We did not find any significant difference in nausea/vomiting based on treatment technique. CONCLUSION: Proton technique significantly influenced olfactory perception with greater rates of phantosmia with PBS compared to PS. Prospective studies should be performed to determine the cause of these findings and determine techniques to minimize phantosmia during radiation therapy.


Assuntos
Neoplasias Encefálicas , Radiação Cranioespinal , Transtornos do Olfato , Terapia com Prótons , Masculino , Feminino , Humanos , Criança , Pré-Escolar , Adolescente , Adulto Jovem , Adulto , Prótons , Radiação Cranioespinal/efeitos adversos , Radiação Cranioespinal/métodos , Estudos Prospectivos , Neoplasias Encefálicas/radioterapia , Neoplasias Encefálicas/etiologia , Terapia com Prótons/efeitos adversos , Terapia com Prótons/métodos , Vômito/induzido quimicamente , Transtornos do Olfato/induzido quimicamente , Náusea/induzido quimicamente , Dosagem Radioterapêutica
2.
Neuro Oncol ; 25(9): 1686-1697, 2023 09 05.
Artigo em Inglês | MEDLINE | ID: mdl-37029730

RESUMO

BACKGROUND: Data on clinical outcomes for base of skull (BOS) chordomas in the pediatric population is limited. We report patient outcomes after surgery and proton radiotherapy (PRT). METHODS: Pediatric patients with BOS chordomas were treated with PRT or combined proton/photon approach (proton-based; for most, 80% proton/20% photon) at the Massachusetts General Hospital from 1981 to 2021. Endpoints of interest were overall survival (OS), disease-specific survival, progression-free survival (PFS), freedom from local recurrence (LC), and freedom from distant failure (DC). RESULTS: Of 204 patients, median age at diagnosis was 11.1 years (range, 1-21). Chordoma location included 59% upper and/or middle clivus, 36% lower clivus, 4% craniocervical junction, and 1% nasal cavity. Fifteen (7%) received pre-RT chemotherapy. Forty-seven (23%) received PRT, and 157 (77%) received comboRT. Median total dose was 76.7 Gy (RBE) (range, 59.3-83.3). At a median follow-up of 10 years (interquartile range, 5-16 years), 56 recurred. Median OS and PFS were 26 and 25 years, with 5-, 10-, and 20-year OS and PFS rates of 84% and 74%, 78% and 69%, and 64% and 64%, respectively. Multivariable actuarial analyses showed poorly differentiated subtype, radiographical progression prior to RT, larger treatment volume, and lower clivus location to be prognostic factors for worse OS, PFS, and LC. RT was well tolerated at a median follow-up of 9 years (interquartile range, 4-16 years). Side effects included 166 patients (80%) with mild/moderate acute toxicities, 24 (12%) patients with late toxicities, and 4 (2%) who developed secondary radiation-related malignancies. CONCLUSION: This is the largest cohort of BOS chordomas in the literature, pediatric and/or adult. High-dose PRT following surgical resection is effective with low rates of late toxicity.


Assuntos
Condrossarcoma , Cordoma , Terapia com Prótons , Neoplasias da Base do Crânio , Adulto , Humanos , Criança , Lactente , Pré-Escolar , Adolescente , Adulto Jovem , Prótons , Cordoma/radioterapia , Cordoma/cirurgia , Cordoma/patologia , Neoplasias da Base do Crânio/radioterapia , Neoplasias da Base do Crânio/cirurgia , Condrossarcoma/radioterapia , Condrossarcoma/cirurgia , Base do Crânio/patologia , Resultado do Tratamento , Seguimentos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA